Novel hyperkinetic dystonia-like manifestation and neurological disease course of Swedish Gaucher patients

嗅觉减退 肌张力障碍 帕金森病 儿科 医学 焦虑 冷漠 癫痫 共济失调 酶替代疗法 萧条(经济学) 疾病 运动障碍 精神科 内科学 传染病(医学专业) 经济 宏观经济学 2019年冠状病毒病(COVID-19)
作者
Maciej Machaczka,Martin Paucar,Cecilia Kämpe Björkvall,Nicholas J. Smith,Timothy M. Cox,Lars Forsgren,Per Svenningsson
出处
期刊:Blood Cells Molecules and Diseases [Elsevier BV]
卷期号:68: 86-92 被引量:19
标识
DOI:10.1016/j.bcmd.2016.10.011
摘要

Neuronopathic Gaucher disease type 3 (GD3) is frequent in northern Sweden, whereas GD1 is found throughout the country. In a nation-wide study, we examined neurological manifestations and clinical course in 12 patients with GD3 and 13 patients with GD1.The patients were evaluated by standardized neurological assessments. Every sixth month, the GD3 patients were rated with the modified Severity Scoring Tool. At baseline and at the 3years follow-up, patients underwent University of Pennsylvania Smell Identification Test, Montreal Cognitive Assessment and Hospital Anxiety and Depression Scale. When clinical signs were present, additional examinations were undertaken.Marked clinical heterogeneity was evident in both GD3 and GD1 groups. Several GD3 patients had a hitherto unreported rapid and repetitive dystonia-like hyperkinetic movement disorder. Most patients with GD3 have abnormalities of horizontal gaze, ataxia and focal epilepsy, some also had cognitive impairment, anxiety and hyposmia. Six GD3 patients, all homoallelic for L444P GBA1 mutations, have lived beyond 40years of age; and none has developed Parkinsonism. Two of the GD1 patients suffer from Parkinsonism; mild to complete hyposmia was present in six GD3 and five GD1 patients. Neither the group of GD3 nor GD1 patients had detectable progression of their neurological manifestations.These middle-aged and older Swedish GD3 or GD1 patients are clinically stable over time. However, we have identified unusual clinical features, discordant phenotypes and a hyperkinetic dystonia-like movement disorder which appears unique to this Swedish disease variant and expands the phenotype for GD.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
HHH完成签到,获得积分10
1秒前
2秒前
玄梓寒发布了新的文献求助10
2秒前
外向梦柏发布了新的文献求助10
2秒前
湖工大保卫处完成签到,获得积分10
2秒前
12345完成签到,获得积分10
4秒前
火星上的以筠完成签到,获得积分10
4秒前
隐形曼青应助Sherme采纳,获得10
5秒前
5秒前
5秒前
Sew东坡完成签到,获得积分0
6秒前
帅气诗槐发布了新的文献求助30
6秒前
champagnefeng完成签到,获得积分10
7秒前
薏米人儿完成签到 ,获得积分10
8秒前
9秒前
稳重的向松完成签到,获得积分20
10秒前
科研通AI6.2应助Tcell采纳,获得10
10秒前
10秒前
无与伦比完成签到,获得积分10
11秒前
啊aa发布了新的文献求助10
11秒前
11秒前
13秒前
单身的忆南完成签到,获得积分10
13秒前
万能图书馆应助简绮采纳,获得10
14秒前
genhex发布了新的文献求助10
14秒前
你嵙这个期刊没买应助Alex采纳,获得10
14秒前
元昭诩应助zyk采纳,获得10
15秒前
科研通AI6.1应助LUNWENREQUEST采纳,获得10
15秒前
李丹阳发布了新的文献求助10
15秒前
orixero应助尹不愁采纳,获得20
16秒前
scott_zip完成签到 ,获得积分10
17秒前
20秒前
666完成签到,获得积分10
20秒前
lvbowen发布了新的文献求助10
22秒前
CipherSage应助zzz采纳,获得10
23秒前
mumian完成签到 ,获得积分10
23秒前
23秒前
666发布了新的文献求助10
23秒前
藏识完成签到,获得积分10
25秒前
26秒前
高分求助中
Cronologia da história de Macau 1600
Treatment response-adapted risk index model for survival prediction and adjuvant chemotherapy selection in nonmetastatic nasopharyngeal carcinoma 1000
Lloyd's Register of Shipping's Approach to the Control of Incidents of Brittle Fracture in Ship Structures 1000
BRITTLE FRACTURE IN WELDED SHIPS 1000
Intentional optical interference with precision weapons (in Russian) Преднамеренные оптические помехи высокоточному оружию 1000
Atlas of Anatomy 5th original digital 2025的PDF高清电子版(非压缩版,大小约400-600兆,能更大就更好了) 1000
Current concept for improving treatment of prostate cancer based on combination of LH-RH agonists with other agents 1000
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 纳米技术 计算机科学 化学工程 生物化学 物理 复合材料 内科学 催化作用 物理化学 光电子学 细胞生物学 基因 电极 遗传学
热门帖子
关注 科研通微信公众号,转发送积分 6192644
求助须知:如何正确求助?哪些是违规求助? 8019932
关于积分的说明 16689605
捐赠科研通 5288942
什么是DOI,文献DOI怎么找? 2818849
邀请新用户注册赠送积分活动 1798434
关于科研通互助平台的介绍 1661815